Care pathway in patients after myocardial infarction in Denmark − healthcare and drug utilization
These findings show that a large proportion of patients are not receiving lipid lowering therapy or are not monitored according to guidelines one year after an MI. This suggests a further need for monitoring MI patients with LDL-C levels and healthcare visits.
Authors
- Kristoffer Jarlov Jensen (ORCID: https://orcid.org/0000-0001-9687-5706)
- Susanne Hansen (ORCID: https://orcid.org/0000-0002-9550-6703)
- Janne Petersen (ORCID: https://orcid.org/0000-0001-7323-2548)
- Henrik Kjærulf Jensen (ORCID: https://orcid.org/0000-0003-1802-4302)
- Marius Mølsted Flege (ORCID: https://orcid.org/0000-0003-4948-1581)
- Theresa Kleinschmidt
- Morten Krogh Christiansen (ORCID: https://orcid.org/0000-0002-3894-888X)
- Charlotte Ottar Merland
Institutions
- University of Copenhagen (DK)
- Aarhus University (DK)
- Frederiksberg Hospital (DK)
- Aarhus University Hospital (DK)
- Regionshospitalet Viborg (DK)
- Center for Clinical & Basic Research (DK)
- Leo Pharma (Denmark) (DK)
Publication Details
- Journal
- IJC Heart & Vasculature
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.ijcha.2025.101809
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen